Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome + PD-1 Blockade in Recurrent/Metastatic NPC
NCT06472713Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone in nasopharyngeal carcinoma (NPC). Primary endpoint: Objective Response Rate at 2 years. Started Jul 2024; status: recruiting.
02
Drugs
mitoxantrone
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06472713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472713.